2023-12-12 07:41:19 ET
DENVER, Colo., Dec 12, 2023 ( www.247marketnews.com )- C4 Therapeutics, Inc. (NASDAQ: CCCC) stated, this morning, that it entered into an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
C4T is trading at $1.54, up $0.36 (+30.51%), on 3.8M shares traded.
Its 52-week range is $1.06 to $9.41. This hit a new 52-week low last week and may be driven higher by short covering.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MNâ€) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an …
The post License and Research Collaboration with Merck has this Small Cap on Fire appeared first on 24/7 Market News .
For further details see:
License and Research Collaboration with Merck has this Small Cap on Fire
Disclaimer
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of C4 Therapeutics Inc. (CCCC) and does not buy, sell, or trade any shares of (CCCC). This article does not provide a professional analysis of a (CCCC) financial position. (CCCC) financial position and all other information regarding the featured Company should be verified directly with (CCCC). Please read our full disclaimer for more detailed information.
